The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase

Journal of Virology

Volumn 85, Issue 20, 2011, Pages 10884-10893

  Goldner, Thomas ^a   Hewlett, Guy ^a   Ettischer, Nicole ^b   Ruebsamen Schaeff, Helga ^a   Zimmermann, Holger ^a   Lischka, Peter ^a  

^a AiCuris GmbH   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AIC 246; CIDOFOVIR; FOSCARNET SODIUM; GANCICLOVIR; LETERMOVIR; PLACEBO; TERMINASE; TOMEGLOVIR; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS PROTEIN;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CONTROLLED STUDY; CROSS RESISTANCE; DNA PACKAGING; DNA SYNTHESIS INHIBITION; DRUG TARGETING; EMBRYO; GENOTYPE; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; NONHUMAN; OPEN READING FRAME; POINT MUTATION; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; VIRION; VIROGENESIS; VIRUS GENOME; VIRUS INHIBITION; VIRUS MUTANT; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; DNA MUTATIONAL ANALYSIS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; ENDODEOXYRIBONUCLEASES; HUMANS; MUTATION, MISSENSE; VIRAL STRUCTURAL PROTEINS; VIRUS ASSEMBLY; VIRUS REPLICATION;

HUMAN HERPESVIRUS 5;

EID: 80055021608     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.05265-11     Document Type: Article

References (50)

1. Andrei, G., C. E. De, and R. Snoeck. 2009. Drug targets in cytomegalovirus infection. Infect. Disord. Drug Targets 9:201-222.
2. Andreoni, M., M. Faircloth, L. Vugler, and W. J. Britt. 1989. A rapid microneutralization assay for the measurement of neutralizing antibody reactive with human cytomegalovirus. J. Virol. Methods 23:157-167.
3. Antinone, S. E., and G. A. Smith. 2010. Retrograde axon transport of herpes simplex virus and pseudorabies virus: a live-cell comparative analysis. J. Virol. 84:1504-1512.
4. Becke, S., et al. 2010. Optimized recombinant dense bodies of human cytomegalovirus efficiently prime virus specific lymphocytes and neutralizing antibodies without the addition of adjuvant. Vaccine 28:6191-6198.
5. Biswas, S., M. Swift, and H. J. Field. 2007. High frequency of spontaneous helicase-primase inhibitor (BAY 57-1293) drug-resistant variants in certain laboratory isolates of HSV-1. Antivir. Chem. Chemother. 18:13-23.
6. Bogner, E. 2002. Human cytomegalovirus terminase as a target for antiviral chemotherapy. Rev. Med. Virol. 12:115-127.
7. Bogner, E., K. Radsak, and M. F. Stinski. 1998. The gene product of human cytomegalovirus open reading frame UL56 binds the pac motif and has specific nuclease activity. J. Virol. 72:2259-2264.
8. Borst, E. M., and M. Messerle. 2005. Analysis of human cytomegalovirus oriLyt sequence requirements in the context of the viral genome. J. Virol. 79:3615-3626.
9. Borst, E. M., K. Wagner, A. Binz, B. Sodeik, and M. Messerle. 2008. The essential human cytomegalovirus gene UL52 is required for cleavage-packaging of the viral genome. J. Virol. 82:2065-2078.
10. Buerger, I., et al. 2001. A novel nonnucleoside inhibitor specifically targets cytomegalovirus DNA maturation via the UL89 and UL56 gene products. J. Virol. 75:9077-9086.
11. Champier, G., et al. 2008. Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. Antivir. Ther. 13:643-654.
12. Coen, D. M., P. A. Furman, P. T. Gelep, and P. A. Schaffer. 1982. Mutations in the herpes simplex virus DNA polymerase gene can confer resistance to 9-beta-D-arabinofuranosyladenine. J. Virol. 41:909-918.
13. Dittmer, A., and E. Bogner. 2005. Analysis of the quaternary structure of the putative HCMV portal protein PUL104. Biochemistry 44:759-765.
14. Dittmer, A., J. C. Drach, L. B. Townsend, A. Fischer, and E. Bogner. 2005. Interaction of the putative human cytomegalovirus portal protein pUL104 with the large terminase subunit pUL56 and its inhibition by benzimidazole-D-ribonucleosides. J. Virol. 79:14660-14667.
15. Drew, W. L. 2010. Cytomegalovirus resistance testing: pitfalls and problems for the clinician. Clin. Infect. Dis. 50:733-736.
16. Eid, A. J., and R. R. Razonable. 2010. New developments in the management of cytomegalovirus infection after solid organ transplantation. Drugs 70:965-981.
17. Evers, D. L., et al. 2002. Interactions among antiviral drugs acting late in the replication cycle of human cytomegalovirus. Antivir. Res. 56:61-72.
18. Fowler, K. B., and S. B. Boppana. 2006. Congenital cytomegalovirus (CMV) infection and hearing deficit. J. Clin. Virol. 35:226-231.
19. Gibson, W. 2006. Assembly and maturation of the capsid, p. 231-243. In M. J. Reddehase (ed.), Cytomegaloviruses: molecular biology and immunology. Horizon Scientific Press, Hethersett, Norwich, United Kingdom.
20. Griffiths, P. D., and S. Walter. 2005. Cytomegalovirus. Curr. Opin. Infect. Dis. 18:241-245.
21. Jiang, X. J., et al. 2008. UL74 of human cytomegalovirus contributes to virus release by promoting secondary envelopment of virions. J. Virol. 82:2802-2812.
22. Kaul, D. R., et al. First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-cmv compound aic246. Am. J. Transplant., in press.
23. Komazin, G., L. B. Townsend, and J. C. Drach. 2004. Role of a mutation in human cytomegalovirus gene UL104 in resistance to benzimidazole ribonucleosides. J. Virol. 78:710-715.
24. Kotton, C. N., et al. 2010. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 89:779-795.
25. Kropeit, D., et al. 2010. Phase I safety and PK data of the novel anti-HCMV terminase inhibitor AIC246, abstr. 1994. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother.
26. Krosky, P. M., et al. 1998. Resistance of human cytomegalovirus to benzimidazole ribonucleosides maps to two open reading frames: UL89 and UL56. J. Virol. 72:4721-4728.
27. Li, C. R., P. D. Greenberg, M. J. Gilbert, J. M. Goodrich, and S. R. Riddell. 1994. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 83:1971-1979.
28. Lischka, P., et al. 2010. In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246. Antimicrob. Agents Chemother. 54:1290-1297.
29. Lischka, P., O. Rosorius, E. Trommer, and T. Stamminger. 2001. A novel transferable nuclear export signal mediates CRM1-independent nucleocytoplasmic shuttling of the human cytomegalovirus transactivator protein pUL69. EMBO J. 20:7271-7283.
30. Lischka, P., G. Sorg, M. Kann, M. Winkler, and T. Stamminger. 2003. A nonconventional nuclear localization signal within the UL84 protein of human cytomegalovirus mediates nuclear import via the importin alpha/beta pathway. J. Virol. 77:3734-3748.
31. Lischka, P., Z. Toth, M. Thomas, R. Mueller, and T. Stamminger. 2006. The UL69 transactivator protein of human cytomegalovirus interacts with DEXD/H-box RNA helicase UAP56 to promote cytoplasmic accumulation of unspliced RNA. Mol. Cell. Biol. 26:1631-1643.
32. Lischka, P., and H. Zimmermann. 2008. Antiviral strategies to combat cytomegalovirus infections in transplant recipients. Curr. Opin. Pharmacol. 8:541-548.
33. Ljungman, P., M. Hakki, and M. Boeckh. 2010. Cytomegalovirus in hematopoietic stem cell transplant recipients. Infect. Dis. Clin. N. Am. 24:319-337.
34. Lorz, K., et al. 2006. Deletion of open reading frame UL26 from the human cytomegalovirus genome results in reduced viral growth, which involves impaired stability of viral particles. J. Virol. 80:5423-5434.
35. Lurain, N. S., and S. Chou. 2010. Antiviral drug resistance of human cytomegalovirus. Clin. Microbiol. Rev. 23:689-712.
36. McVoy, M. A., and D. E. Nixon. 2005. Impact of 2-bromo-5,6-dichloro-1-beta-D-ribofuranosyl benzimidazole riboside and inhibitors of DNA, RNA, and protein synthesis on human cytomegalovirus genome maturation. J. Virol. 79:11115-11127.
37. Mettenleiter, T. C., B. G. Klupp, and H. Granzow. 2009. Herpesvirus assembly: an update. Virus Res. 143:222-234.
38. Mocarski, E. S., T. Shenk, and R. Pass. 2007. Cytomegalovirus. In D. M. Knipe et al. (ed.), Fields virology, 5th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
39. Nixon, D. E., and M. A. McVoy. 2004. Dramatic effects of 2-bromo-5,6-dichloro-1-beta-D-ribofuranosyl benzimidazole riboside on the genome structure, packaging, and egress of guinea pig cytomegalovirus. J. Virol. 78:1623-1635.
40. Reefschlaeger, J., et al. 2001. Novel non-nucleoside inhibitors of cytomegaloviruses (BAY 38-4766): in vitro and in vivo antiviral activity and mechanism of action. J. Antimicrob. Chemother. 48:757-767.
41. Scheffczik, H., C. G. Savva, A. Holzenburg, L. Kolesnikova, and E. Bogner. 2002. The terminase subunits pUL56 and pUL89 of human cytomegalovirus are DNA-metabolizing proteins with toroidal structure. Nucleic Acids Res. 30:1695-1703.
42. Schreiber, A., et al. 2009. Antiviral treatment of cytomegalovirus infection and resistant strains. Expert. Opin. Pharmacother. 10:191-209.
43. Scott, G. M., A. Weinberg, W. D. Rawlinson, and S. Chou. 2007. Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates. Antimicrob. Agents Chemother. 51:89-94.
44. Snydman, D. R. 2010. Leflunomide: a small step forward in meeting the urgent need for treatment of drug-resistant cytomegalovirus infection. Transplantation 90:362-363.
45. Tavalai, N., M. Kraiger, N. Kaiser, and T. Stamminger. 2008. Insertion of an EYFP-pp71 (UL82) coding sequence into the human cytomegalovirus genome results in a recombinant virus with enhanced viral growth. J. Virol. 82:10543-10555.
46. Tischer, B. K., E. J. von Kaufer, and N. Osterrieder. 2006. Two-step red-mediated recombination for versatile high-efficiency markerless DNA manipulation in Escherichia coli. Biotechniques 40:191-197.
47. Townsend, L. B., R. V. Devivar, S. R. Turk, M. R. Nassiri, and J. C. Drach. 1995. Design, synthesis, and antiviral activity of certain 2,5,6-trihalo-1-(beta-D-ribofuranosyl)benzimidazoles. J. Med. Chem. 38:4098-4105.
48. Underwood, M. R., et al. 1998. Inhibition of human cytomegalovirus DNA maturation by a benzimidazole ribonucleoside is mediated through the UL89 gene product. J. Virol. 72:717-725.
49. Yu, D., M. C. Silva, and T. Shenk. 2003. Functional map of human cytomegalovirus AD169 defined by global mutational analysis. Proc. Natl. Acad. Sci.U. S. A. 100:12396-12401.
50. Zimmermann, H., et al. 2009. A novel non-nucleoside compound with activity against human cytomegalovirus-overview of clinical trials and resistance breaking activity, abstr. V1256b. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother.